Apolipoprotein L1 (APOL1) Variants (Vs) a possible link between Heroin-associated Nephropathy (HAN) and HIV-associated Nephropathy (HIVAN)

Xiqian Lan¹, T. K. S. Rao², Praveen N. Chander³, Karl Skorecki⁴ and Pravin C. Singhal¹*

¹ Hofstra North Shore-LI School of Medicine, Long Island, NY, USA, ² Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA, ³ Department of Pathology, New York Medical College, Valhalla, NY, USA, ⁴ Technion Institute of Technology and Rambam Medical Center, Haifa, Israel

In 1970s, Heroin-associated Nephropathy (HAN), one form of focal and segmental glomerulosclerosis (FSGS), was a predominant cause of End-stage Kidney Disease (ESKD) in African-Americans (AAs). In 1980s, with the surge of Acquired Immune Deficiency Syndrome (AIDS) in AAs, HAN more or less disappeared, and the incidence of Human Immunodeficiency Virus associated Nephropathy (HIVAN) markedly increased. Recent studies in AAs have identified APOL1 variants (Vs) as a major risk factor for the development and progression of non-diabetic kidney diseases including idiopathic FSGS and hypertension-attributed nephrosclerosis. These observations have also offered partial insights into the mechanisms of development, and higher rate of occurrence of both HAN and HIVAN in AAs. AAs with APOL1Vs develop idiopathic FSGS at four-fold higher rate compared to European Americans (EAs). Similarly, HIV infected AAs with APOL1Vs (if not on antiviral therapy), risk a 50% (10-fold greater) chance of developing HIVAN. It has been suggested that APOL1Vs expression may render podocytes more vulnerable to various types of injury: bacterial, viral, and others. However, in addition to genetic variants, additional factors such as persistence of a second hit may determine the nature and severity of glomerular disease. In patients with HAN, heroin or contaminants may have been the offending second insult(s) which caused renal disease in susceptible AA patients. In the 80’s, since heroin-induced second hit was neither consistent nor sustained (depending on drug availability in the street), the disease was masked or replaced HIV infected patients (especially in untreated subjects), by an overwhelming second hit by the virus which was both intense as well as persistent. It appears that APOL1Vs may be one of the links between the disappearance of HAN and emergence of HIVAN in AA patients.

Keywords: APOL1, heroin nephropathy, HIV-associated nephropathy, podocytes, opiates
Introduction

There has been an explosive growth in illicit drug use in general and in the USA in particular during the last past 45 years. Although being only 4.6% of the world’s population, Americans consume 80% of the global opiates supply and 99% of the global hydrocodone supply (Catalanom et al., 2011). According to CDC, 40% of HIV-infected individuals in the United States are associated with the use of injection drugs; similarly, among injection drug users, 40–45% are HIV infected (CDC, 2010). Thus, use of drugs in patients with HIV infection is an unresolved problem of high relevance. Since factors associated with heroin addiction such as bacterial and viral infections carry the potential to contribute to the development of renal lesions, it is not clear whether it is heroin or its metabolite, morphine, or associated adulterants which are responsible for the entity morphologically described as HAN (Kimmel and Moore, 1997; Freedman et al., 1999; Kimmel et al., 2001; Norris et al., 2001; Satko and Freedman, 2004).

The number of cases of “heroin nephropathy” has been decreasing over the years, despite the increased prevalence of heroin use. Although focal glomerulosclerosis has been a predominant pathological feature in patients with heroin abuse in several studies (Salomon et al., 1972; Freedman et al., 1974; Rao et al., 1977; Friedman and Rao, 1995), but other studies have not shown any uniform pathologic presentation (McGinn et al., 1970; Kilcoyne et al., 1972; Grisham et al., 1976; Llach et al., 1979; Cunningham et al., 1980, 1983; Dettmeyer et al., 1998; do Sameiro Fario et al., 2003). It is not clear whether heroin is contributing to renal lesions in these patients or whether nephropathy is related to demographic, socioeconomic, or genetic factors of individual users (Kimmel and Moore, 1997; Freedman et al., 1999; Kimmel et al., 2001; Norris et al., 2001; Satko and Freedman, 2004).

Focal segmental glomerulosclerosis (FSGS) is the most common type of renal lesions in AA (Kittyakara et al., 2003). Genetic factors do play a role in the development of FSGS but their role has been debated for a long time (Devarajan and Spitzer, 2002; Tucker, 2002; Kittyakara et al., 2003, 2004; Kopp and Winkler, 2003; Winn, 2003; Andreoli, 2004; Orloff et al., 2005). On that account it has been suggested that that black heroin users with FSGS have a genetic susceptibility to the development of renal disease, unrelated to the drug use. Thus, it is not clear whether development of FSGS in drug users is primarily related to genetics or to the drug use. Alternatively, genetic may be a first hit and drug use might be the second hit. Moreover, besides FSGS several other types of renal lesions are associated with heroin use (McGinn et al., 1970; Kilcoyne et al., 1972; Grisham et al., 1976; Llach et al., 1979; Cunningham et al., 1980, 1983; Dettmeyer et al., 1998; do Sameiro Fario et al., 2003).

Heroin-associated Nephropathy (HAN)

In early 1970s, many clinicians observed excessive urinary protein excretion and renal functional abnormalities in heroin addicts. Rao et al. described the natural history of renal disease in heroin addicts who presented with massive proteinuria and focal segmental glomerulosclerosis (FSGS) which progressed to end stage kidney disease (ESKD) in months, and coined the term Heroin-Associated Nephropathy (HAN) (Kilcoyne et al., 1972; Rao et al., 1974, 1977). These patients were mostly young men predominantly of African American (AA) descent residing in large Metropolitan areas (Kilcoyne et al., 1972; Rao et al., 1974, 1977; Cunningham et al., 1983; Friedman, 1983; May et al., 1986). An increased risk for ESKD with an odds ratio of 19.1 was noted for heroin users vs. non-users (Cunningham et al., 1980). In addition to genetic predilection, occurrence of HAN was attributed to bacterial or viral toxins and street contaminants (Rao et al., 1977; Cunningham et al., 1980, 1983). HAN occurrence peaked in late 70’s and early 80’s and accounted for large number of young AA men with ESKD on maintenance dialysis (Cunningham et al., 1983). Renal involvement in heroin addiction manifested in multiple forms including FSGS, amyloidosis (in subcutaneous heroin addicts), endocarditis-associated glomerulonephritis, hepatitis-related glomerulonephritis, and acute renal failure from rhabdomyolysis (Kilcoyne et al., 1972; Rao et al., 1977; Cunningham et al., 1980, 1983; Friedman, 1983; Baldwin et al., 1993; Dettmeyer et al., 1998).

Other investigators found no specific histologic or immunofluorescence pattern in heroin users with renal disease (Llach et al., 1979). They described a spectrum of disease pattern including FSGS, minimal change disease, MPGN, mesangial proliferation, dysproteinemias, and diabetic nephropathy (Llach et al., 1979).

Unfortunately, there is no prospective controlled trial or well-designed epidemiologic studies have been carried out to confirm the role of heroin in the development of heroin nephropathy. Previous studies have been conducted predominantly on hospital-admitted patients and they may have several other confounding factors, which might have been missed.

Opiates and Kidney Disease

Clinical studies indicated that opiate addicts are at an increased risk for progressive chronic kidney disease (Baldwin et al., 1993; Perneger et al., 2001). Since mesangial expansion is considered to be a precursor of focal glomerulosclerosis, we evaluated the effect of opiates on mesangial cell proliferation and matrix synthesis. In vitro studies have shown that morphine (a metabolite of heroin) directly stimulates proliferation of glomerular epithelial cells, mesangial cells, fibroblasts, and medullary interstitial cells (Singhal et al., 1992, 1997, 1998; Patel et al., 2003a). Morphine at higher concentration inhibited growth of mesangial cells, fibroblasts, and glomerular epithelial cells (Singhal et al., 1992, 1997, 1998; Patel et al., 2003a). It stimulates the production of superoxide by macrophages and nitric oxide by mesangial cells (Singhal et al., 1994; Kapasi et al., 2000). Morphine exerts a bimodal effect on heme oxygenase activity in glomerular epithelial cells, macrophages, and mesangial cells (Patel et al., 2003b) and also promoted macrophage apoptosis through the generation of transforming growth factor-β and reactive oxygen species (Singhal et al., 2000). Morphine-induced macrophage activity stimulated mesangial cell proliferation (Singhal et al., 1996a). In vivo studies, morphine inhibited matrix proteinases and promoted accumulation of matrix and IgG complexes in the mesangium (Sagar et al., 1994; Singhal et al., 1996a).
Morphine also enhanced accumulation of IgG complexes in
the mesangium of rats with anti-thymoglobulin-induced kidney
injury (Pan and Singhal, 1994; Singhal et al., 1996b); additionally,
it stimulated deposition of ferritin-antiferritin complexes in
glomerular mesangium of rats (Singhal et al., 1995). Short-term
administration of morphine invoked podocyte injury in the form
of effacement of foot processes and down regulation of nephrin
expression by podocytes (Lan et al., 2013). Morphine promoted
mesangial cell proliferation, glomerulomegaly, and proteinuria in
control as well as in sickle cell mice (Weber et al., 2008, 2012).
All these in vitro and in vivo studies suggested that morphine
has potential to cause mesangial expansion, a precursor of FSGS.
However, none of these models represent classical phenotype of
HAN.

**Human Immunodeficiency Virus-associated Nephropathy (HIVAN)**

A decade after reporting HAN, Rao et al. described another
group of patients, exclusively young AAs, both heroin addicts
and non-addicts with the Acquired Immunodeficiency syndrome
(AIDS), who presented with massive proteinuria, FSGS, rapidly
progressing to ESKD (Rao et al., 1984, 1987; Rao and Friedman,
1989). Initially, this entity was referred to as AIDS associated
nephropathy, but with the identification of causative agent
Human Immunodeficiency Virus (HIV), these authors coined
the term HIVAN (Rao and Friedman, 1989). Interestingly,
an increase in the incidence of HIVAN was associated with
a dramatic decline in new cases of HAN, despite growing
number in heroin addiction population (Friedman and Rao,
1995; Monahan et al., 2001). Collapsing form of FSGS is the
renal lesion typically seen in patients with HIVAN (D’Agati et al.,
1989; Valeri et al., 1996). Numerous studies which analyzed
the risk factors for development of renal disease, have shown
that more than 90% of patients with HIV associated FSGS are
AAs (Bourgoignie et al., 1989; Haley et al., 2001). Idiopathic
FSGS and its collapsing variants are also commonest causes of
non-diabetic renal syndromes in AAs (Valeri et al., 1996).

All these observations has led to the speculation that
 genetic component is a major risk factor for development and
progression of renal disease in AAs. However, this concept was
a speculation until recent studies which focused on genetic variants
are providing valuable evidence in support of this hypothesis.

Even in the experimental models of HIVAN in transgenic
mice, susceptibility to kidney disease is influenced by HIV
genes and host genetic variants (Rappaport et al., 1994). The
initial Tg26 mouse line (model of HIVAN) was generated on
the FVB/N inbred mouse strain. This strain was susceptible
to develop renal lesions, however, Tg26 mice bred onto the
mixed FVB/CAST background mouse strain and others did not
develop renal lesions (Gharavi et al., 2004). Genome-wide linkage
analysis revealed mouse chromosome 3A1 to 3 region an
HIV-susceptibility locus (Chan et al., 2009). Replacement
of the FVB/N allele in this locus by the CAST allele induced
accelerated disease progression. In addition to Tg26, several other
transgenic models have been generated to determine the role of
specific HIV genes in the pathogenesis of HIVAN. Expression
of an HIV Δgag/pol/nef transgene in mouse induced FSGS
and microcystic tubular dilation but not podocyte proliferation
(Kajiyama et al., 2000); however, when this transgenic mice were
back-crossed to a Nef-only transgenic mice, the severity of renal
lesions increased (Dickie et al., 1993); these findings indicated the
role of Nef and another gene in HIVAN pathogenesis. In another
study, in Tg26 mouse model, vpr, nef, or both were additionally
deleted; only mice carrying an intact Vpr gene developed FSGS
with tubular dilation (Dickie et al., 2004). All these studies
indicate the role of specific HIV genes in the pathogenesis in
HIVAN.

**Apolipoprotein (APO) L1**

This gene is located at chromosome 22q13.1, and encodes the
minor APOL1 component of High-Density Lipoprotein (HDL).
It is expressed in liver, pancreas, kidney, brain, macrophages,
endothelial, and several other cell types (Bergman et al., 1996;
Duchateau et al., 1997). The G1 variant (rs73885319) is a
compound missense mutation (S342G:I384M), encoding two
non-synonymous amino acids. G2 variant is a 6 bp in-frame
deletion which has resulted in the loss of two amino acids
(N388 and Y389) at the C-terminal helix of APOL1 (Dunham
et al., 1999; Genovese et al., 2013). Approximately 34% of AAs
possess one of the two risk variants and approximately 13%
have both coding variants (Dunham et al., 1999; Wasser et al.,
2012; Genovese et al., 2013). In the United States, approximately
3 million AAAs carry both risk alleles. In contrast, APOL1 risk
variants occur infrequently in EAs, approximately 0.3% carry G1
and 0.1% G2 alleles.

**APOL1 and Kidney Disease**

AAs develop higher rates of progressive nephropathy, including
idiopathic FSGS, HIVAN, and hypertension-attributed ESKD as
compared to European Americans (EAs) (Kopp et al., 2011;
Quaggin and George, 2011; Wasser et al., 2012). This disparity
is most pronounced in patients with HIV-infection who are
not taking highly active antiretroviral drugs. The rate of the
development of HIVAN is greater than 10-fold in such untreated
subjects (US Renal Data System, 2009). This overwhelming
population disparity between AAs and EAs and, greater familial
clustering among AA, point to a prominent contribution of
underlying genetic factor(s) (Freedman et al., 1999). Recent
evidence has shown that this major health disparity is strongly
associated with two coding sequence variants (G1 and G2) in
APOL1 (Genovese et al., 2010; Tzur et al., 2010; Friedman et al.,
2011; Foster et al., 2013). In a recent study, human podocytes
expressing APOL1 variants (G1 and G2) displayed enhanced
lyosomal swelling and podocyte necrosis (Lan et al., 2014).
Moreover, even an overexpression of APOL1 wild type was
associated with podocyte toxicity. Interestingly, renal biopsy
specimens in patient with APOL1 variants smooth muscle cells
displayed enhanced APOL1 expression (Madhavan et al., 2011).
These findings prompted us to look into a possibility that smooth
muscle may be serving as an endocrine or paracrine source of
APOL1 for delivery to podocytes (Lan et al., 2015). This is a
plausible hypothesis but needs to be tested in future studies.
Since only 4% out of 13% of AAs expressing APOL1 variants develop
kidney disease, it appears that in addition to the genetic markers,
there has to be additional insult to make podocytes vulnerable to injury. Persistent viral load in the blood and continued exposure to virus accounts for higher rate of HIVAN in this vulnerable population, further supporting this notion.

Renal biopsy studies in patients with FSGS and HIVAN revealed lower expression of APOL1 in podocytes when compared other cells (Madhavan et al., 2011). In a recent report, no correlation was observed between circulating APOL1 levels with HIV infection status or inflammatory mediators in an HIV positive cohort with kidney disease (Bruggeman et al., 2014). Thus, at present it is not clear whether it is locally expressed APOL1 or a burst of circulating APOL1 that contributes to kidney injury. Since there was no relationship between severity of HIV infection and development of kidney disease (Bruggeman et al., 2014), we propose that APOL1-induced vulnerability to HIV effects are more critical for the development of HIVAN rather than the level of viral load.

**Transition of HAN to HIVAN in APOL1Vs Bearing Population**

Disappearance of HAN and appearance of HIVAN in the same population was a puzzle (Friedman and Rao, 1995; Monahan et al., 2001). Investigators who made this observation hypothesized that availability of contaminant-free heroin may account for the disappearance of HAN (Friedman and Rao, 1995). In some earlier studies, Haskell et al. suggested some relationship between HAN and HLA type (Haskell et al., 1988). Recent observations on the role of APOL1 variants in the development of kidney disease in AAs, it appears that heroin may have acted as a trigger for the induction of renal injury in this population. Nevertheless, when the same population was exposed to a stronger and continuous trigger such as HIV infection, the effect of an inconsistent hit such as heroin might have nullified.

**Conclusions**

The predominant renal lesion in heroin users is FSGS; however, a variety of other renal lesions have also been reported. The heterogeneity of renal lesions in heroin users points toward the involvement of multiple factors, including social, economic, and genetic. There is no experimental animal model for heroin nephropathy despite multiple attempts by several investigators; this suggests paucity of an ingredient(s) in the existing models. Recent identification of APOL1 variants contributing to disparity in prevalence of FSGS and HIVAN in AAvs. Caucasians points toward that missing ingredient in experimental animal models (since rodents do not carry APOL1 gene). This also provides an explanation for a decrease in occurrence of HAN with the surge in HIVAN. However, to validate this hypothesis, use of opiates need to be tested in APOL1 transgenic mice in future studies.

**Acknowledgments**

This work was supported by grants RO1DK 098074, RO1DK084910, RO1 DK083931 (PCS) from National Institutes of Health, Bethesda, MD.

**References**

Andreoli, S. P. (2004). Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children. *Adv. Ren. Replace. Ther.* 11, 105–109. doi: 10.1053/jarrt.2003.10.015

Baldwin, D. S., Gallo, G. R., and Neugarten, J. (1993). "Drug abuse with narcotics and other agents," in *Diseases of the Kidney (eds)*, eds R. W. Schrier and C. W. Gottschalk (Boston, MA: Little Brown).

Bergman, S., Key, B. O., Kirk, K. A., Warnock, D. G., and Rostant, S. G. (1996). Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. *Am. J. Kidney Dis.* 27, 341–346. doi: 10.1016/S0272-6386(96)90356-X

Bourgoignie, J. J., Ortiz-Interian, C., Green, D. F., and Roth, D. (1989). Race, a cofactor in HIV-1-associated nephropathy. *Transplant. Proc.* 21, 3899–3901.

Bruggeman, L. A., O'Toole, J. F., Ross, M. D., Madhavan, S. M., Smurzynski, M., Wu, K., et al. (2014). Plasma apolipoprotein L1 levels do not correlate with CKD. *J. Am. Soc. Nephrol.* 25, 634–644. doi: 10.1681/ASN.2013070700

Catalanom, R., Helene, R., White, H. R., Charles, B., Fleming, C. B., and Haggerty, K. P. (2011). Is nonmedicinal prescription opiate use a unique form of illicit drug use? *Addict. Behav.* 36, 79–86. doi: 10.1016/j.addbeh.2010.08.028

CDC. (2010). *Division of HIV/AIDS Prevention*. Atlanta, GA: U.S. Department of Health and Human Services Centers for Disease Control and Prevention.

Chang, K. T., Papeta, N., Martin, J., Zheng, Z., Frankel, R., Klotman, P. E., et al. (2009). Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus on chr 3A1–A3. *Kidney Int.* 75, 366–372. doi: 10.1038/ki.2008.625

Cunningham, E. E., Zielezny, M. A., and Venuto, R. C. (1983). Heroin-associated nephropathy. A clinicopathologic and epidemiologic study. *Am. J. Med.* 68, 47–53. doi: 10.1016/0002-9343(80)90164-3

Cunningham, E. E., Zielezny, M. A., and Venuto, R. C. (1983). Heroin-associated nephropathy. A nationwide problem. *JAMA* 250, 2935–2936. doi: 10.1001/jama.1983.03340210033020

D’Agati, V., Suh, J., Carbone, L., Cheng, J. T., and Appel, G. (1989). Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. *Kidney Int.* 35, 1358–1370.

Dettmeyer, R., Sensing, B., and Madea, B. (1998). Heroin associated nephropathy: a post-mortem study. *Forensic Sci. Int.* 95, 109–116. doi: 10.1016/S0379-0738(98)00082-6

Devarajan, P., and Spitzer, A. (2002). Towards a biological characterization of focal glomerulosclerosis. *Am. J. Kidney Dis.* 39, 625–636. doi: 10.1053/ajkd.2002.31420

Dickie, P., Ramsdell, F., Nottkins, A. L., and Venkatesan, S. (1993). Spontaneous and inducible epidermal hyperplasia in transgenic mice expressing HIV-1 Nef. *Virology* 197, 431–438. doi: 10.1006/viro.1993.1607

Dickie, P., Roberts, A., Uwiera, R., Wittmer, J., Sharma, K., and Kopp, J. (2004). Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV associated nephropathy. *Virology* 322, 69–81. doi: 10.1016/j.virol.2004.01.026

du Sameiro Fario, M., Sampaio, S., Faria, V., and Carvalho, E. (2003). Nephropathy associated with heroin abuse in Caucasian patients. *Nephrol. Dial. Transplant.* 18, 2308–2313. doi: 10.1093/ndt/fgg369

Duchateau, P. N., Pullinger, C. R., Orellana, R. E., Kunitake, S. T., Naya-Vigne, J. O’Connor, P. M., et al. (1997). Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. *J. Biol. Chem.* 272, 25756–25782. doi: 10.1074/jbc.272.41.25576

Dunham, I., Shimizu, N., Roe, B. A., Chissoe, S., Hunt, A. R., Collins, J. E., et al. (1999). The DNA sequence of human chromosome 22. *Nature* 402, 489–495. doi: 10.1038/990031
Satko, S. G., and Freedman, B. I. (2004). The importance of family history on the development of renal disease. *Curr. Opin. Nephrol. Hypertens.* 13, 337–341. doi: 10.1097/00041552-200405000-00012

Singhal, P. C., Gibbons, N., and Abramovici, M. (1992). Long term effects of morphine on mesangial cell proliferation and matrix synthesis. *Kidney Int.* 41, 1560–1570. doi: 10.1038/ki.1992.226

Singhal, P. C., Kapasi, A. A., Franki, N., and Reddy, K. (2000). Morphine-induced macrophage apoptosis: the role of TGF-β. *Immunology* 100, 57–62. doi: 10.1046/j.1365-2567.2000.00007.x

Singhal, P. C., Mattana, J., Garg, P., Arya, M., Shan, Z., Gibbons, N., et al. (1996a). Morphine-induced macrophage activity modulates mesangial cell proliferation and matrix synthesis. *Kidney Int.* 49, 94–102.

Singhal, P. C., Pamarthi, M., Shah, R., Chndra, D., and Gibbons, N. (1994). Morphine stimulates superoxide formation by glomerular mesangial cells. *Inflammation* 18, 293–299. doi: 10.1007/BF01534270

Singhal, P. C., Pan, C. Q., Sagar, S., Gibbons, N., and Valderrama, E. (1995). Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium. *Nephron* 70, 229–234. doi: 10.1159/000188589

Singhal, P. C., Pan, C. Q., Sagar, S., Valderrama, E., and Stahl, R. A. (1996b). Morphine modulates mesangial immunoglobulin G uptake in rats with antithymocyte serum-induced mesangial cell injury. *Nephron* 74, 197–203. doi: 10.1159/000189301

Singhal, P. C., Sharma, P., Gibbons, N., Franki, N., Kapasi, A., and Wagner, J. D. (1997). Effect of morphine on renomedullary interstitial cell proliferation and matrix accumulation. *Nephron* 77, 225–234. doi: 10.1159/000190277

Singhal, P. C., Sharma, P., Sanwal, V., Prasad, A., Kapasi, A., Ranjan, R., et al. (1998). Morphine modulates proliferation of kidney fibroblasts. *Kidney Int.* 53, 350–357. doi: 10.1046/j.1523-1755.1998.00758.x

Tucker, J. K. (2002). Focal segmental glomerulosclerosis in African Americans. *Am. J. Med. Sci.* 323, 90–93. doi: 10.1097/00000441-200202000-00006

Tzur, S., Rosset, S., Shemer, R., Yudkovsky, G., Selig, S., Tarek, A., et al. (2010). Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. *Hum. Genet.* 128, 345–350. doi: 10.1007/s00439-010-0861-0

US Renal Data System. (2009). *US Renal Data System (USRDS). Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.* Bethesda, MD: National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases.

Valeri, A., Barisoni, L., Appel, G. B., Seigle, R., and D’Agati, V. (1996). Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. *Kidney Int.* 50, 1734–1746. doi: 10.1038/ki.1996.493

Wasser, W. G., Tzur, S., Wolday, D., Adu, D., Baumstein, D., Rosset, S., et al. (2012). Population genetics of chronic kidney disease: the evolving story of APOL1. *J. Nephrol.* 25, 603–618. doi: 10.5301/jn.5000179

Weber, M. L., Farooqui, M., Nguyen, J., Ansonoff, M., Pintar, J. E., Hebbel, R. P., et al. (2008). Morphine induces mesangial cell proliferation and glomerulopathy via kappa-opioid receptors. *Am. J. Physiol. Renal Physiol.* 294, F1388–F1397. doi: 10.1152/ajprenal.00389.2007

Weber, M. L., Vang, D., Velho, P. E., Gupta, P., Crosson, J. T., Hebbel, R. P., et al. (2012). Morphine promotes renal pathology in sickle mice. *Int. J. Nephrol. Renovasc. Dis.* 5, 109–118. doi: 10.2147/IJNRD.S33813

Winn, M. P. (2003). Approach to the evaluation of heritable diseases and update on familial focal segmental glomerulosclerosis. *Nephrol. Dial. Transplant* 18(Suppl. 6), 14–20. doi: 10.1093/ndt/gfg1070

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.